Fenwick is representing Treeline Biosciences, a clinical-stage biopharma company that aspires to make medicines at the highest level, in its definitive merger agreement with Standard BioTools Inc. (Nasdaq: LAB).
The combined company will operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders, and targeted therapy antibody-drug conjugates. The proposed transaction would add approximately $450 million in net cash from Standard BioTools to the combined company's balance sheet. At closing, the combined company is expected to have more than $900 million in pro-forma cash, which is expected to fund operations into 2029. More information can be obtained from Treeline’s announcement.
The Fenwick transaction team includes corporate partners Effie Toshav, David Michaels, Rob Freedman, Amanda Rose and Ryan Mitteness, counsel Samuel Fleuter and associates Elsie Cheang, Brandon Ho, Max Krinsky, Connor Haney, Nisha Porchezhiyan and Sarah Marshall; technology transactions partner Stefano Quintini, associates Kehl Sink, Rob Ferrari, Emma Phillips, Kristen Freitas, Phillip Yin, Taylor Muentener, Kiyan Savar and Lily Rose Henein and advisor Sandra Weustink; executive compensation and employee benefits partner Marshall Mort, counsel Laura McIntyre and associates Jonathan Stephenson and Rachel Coffey; privacy and cybersecurity partner Ana Razmazma, counsel Sari Ratican and associate Kayla Tanaka; antitrust and competition partner Steve Alberston and counsel Meredith Mommers; and tax partner William Skinner and associate Justin Folk.